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OBJECTIVE We tested whether a common AMPD1 gene variant is associated with improved cardiovas-
cular (CV) survival in patients with coronary artery disease (CAD).
BACKGROUND Reduced activity of adenosine monophosphate deaminase (AMPD) may increase production
of adenosine, a cardioprotective agent. A common, nonsense, point variant of the AMPD1
gene (C34T) results in enzymatic inactivity and has been associated with prolonged survival
in heart failure.
METHODS Blood was collected from 367 patients undergoing coronary angiography. Genotyping was
done by polymerase chain reaction amplification and restriction enzyme digestion, resulting
in allele-specific fragments. Coronary artery disease was defined as $70% stenosis of $1
coronary artery. Patients were followed prospectively for up to 4.8 years. Survival statistics
compared hetero- (1/2) or homozygotic (2/2) carriers with noncarriers.
RESULTS Patients were 66 6 10 years old; 79% were men; 22.6% were heterozygous and 1.9%
homozygous for the variant AMPD1(2) allele. During a mean of 3.5 6 1.0 years, 52 patients
(14.2%) died, 37 (10.1%) of CV causes. Cardiovascular mortality was 4.4% (4/90) in
AMPD1(2) allele carriers compared with 11.9% (33/277) in noncarriers (p 5 0.046). In
multiple variable regression analysis, only age (hazard ratio, 1.11/year, p , 0.001) and
AMPD1(2) carriage (hazard ratio, 0.36, p 5 0.053) were independent predictors of CV
mortality.
CONCLUSIONS Carriage of a common variant of the AMPD1 gene was associated with improved CV survival
in patients with angiographically documented CAD. The dysfunctional AMPD1(2) allele
may lead to increased cardiac adenosine and increased cardioprotection during ischemic
events. Adenosine monophosphate deaminase-1 genotyping should be further explored in
CAD for prognostic, mechanistic and therapeutic insights. (J Am Coll Cardiol 2000;36:
1248–52) © 2000 by the American College of Cardiology
The adenosine monophosphate deaminase-1 (AMPD1)
gene encodes an isoform of AMP deaminase (AMPD1, also
called myoadenylate deaminase) that is active in muscular
tissue (1). Adenosine monophosphate deaminase-1 occupies
a central position in adenosine nucleotide catabolism, cata-
lyzing the conversion of AMP to inosine monophosphate,
the rate-limiting step for entry into the purine nucleotide
cycle. Adenosine monophosphate deaminase-1 deficiency is
believed to cause exercise-induced myalgias and early fatigue
in skeletal muscle (1–3). A common polymorphism in axon
2 of AMPD1, present in about 25% of Caucasians, causes a
C to T transition at nucleotide 34 (C34T) (2,3). This
nonsense transition encodes for a truncated, inactive en-
zyme. A reduced activity of AMPD1 may increase persis-
tence of adenosine (3,4), a cardioprotective molecule (5).
Recently, the C34T variant of AMPD1 has been reported to
be associated with prolonged survival in heart failure (6,7).
We tested whether it also is more broadly associated with
improved cardiovascular (CV) survival in patients with
coronary artery disease (CAD) at high risk for future
ischemic events.
METHODS
Study objectives. We tested whether carriage of the com-
mon variant allele of the AMPD1 gene, (AMPD1[2]) was
associated with a reduced risk of CV death in patients with
documented CAD. We also tested its association with
all-cause mortality.
Study population. Study subjects came from a consecutive
series of clinically stable patients of any age and either
gender who underwent coronary angiography, were shown
to have severe CAD, consented for a blood draw at the time
of angiography (for confidential blood bank studies ap-
proved by the hospital’s institutional review board) and were
followed until death or for .2.5 years from entry. Subjects
were primarily residents of Utah, a population ethnically
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primarily of Northern European descent and genetically
similar to the general U.S. Caucasian population (8).
Data collection. At the time of angiography, key demo-
graphic characteristics were recorded on standard data
forms, including age, gender and history of recent or remote
myocardial infarction (MI) (9). Determination of presence
and severity of CAD was made by each patient’s attending
cardiologist, who was unaware of AMPD1 genotypes, using
a format modified after the Coronary Artery Surgery Study
protocol (9,10). Severe CAD was defined as the presence of
$1 coronary lesions of $70% diameter stenosis in $1 major
coronary artery or its primary branch. Mild or absent CAD
cases were excluded from this study of secondary risk. Index
angiography occurred between August 1994 and December
1997.
Assessment of patient outcomes. The study patient co-
hort was followed until death or December 1998 (mean,
3.5 6 1.0 years of follow-up, range 2.5 to 4.8 years). Each
subject was interviewed through a telephone survey that
determined the subject’s medical history since the index
hospitalization. Deaths were determined when possible
from a family member. Deaths were verified and other
deaths determined as of March 1999 by a search of a
national Social Security database. Subjects unable to be
contacted by telephone but not listed as deceased by the
national database were considered to be alive. Follow-up
using the database allowed for 100% assessment of survival
within the cohort.
DNA extraction. Approximately 20 ml to 30 ml of blood
was withdrawn by venipuncture at the time of coronary
angiography, collected in ethylenediaminetetraacetic acid,
refrigerated at 4°C and processed within 24 h. The leuko-
cyte buffy coat was separated by centrifugation, and genomic
DNA was extracted using a standard phenol:chloroform
method as previously described (11).
DNA genotyping. To identify the AMPD1 C34T variant
genotypes, polymerase chain reaction amplification was
performed with the following primers, as previously pub-
lished (12):
AMPD1 59 CAT ACA GCT GAA GAG ACA 39
AMPD2 59 AAC ACT GCT GAA AAA TAG 39
Amplification reactions were performed in 15 ml volumes
containing the two primers. Genotyping was performed as
previously reported (13). The reaction products were visu-
alized by electrophoresis through a 2% agarose gel contain-
ing ethidium bromide.
Statistical considerations. Comparisons of characteristics
of survivors and nonsurvivors used chi-square (categorical
variables) or unpaired t testing (continuous variables). Al-
lelic and genotypic frequencies were determined from ob-
served counts. Comparisons between allelic or genotypic
frequency distributions used chi-square analysis. Hetero-
(1/2) or homozygotic (2/2) carriers were compared with
noncarriers (wild type genotype, [1/1]) using survival
statistics. The univariate predictive value of AMPD1(2)
carriage for CV and total survival was tested using Kaplan-
Meier analysis and log-rank statistics. Cox logistic regres-
sion analysis (stepwise, backward logistic regression ap-
proach) was then used to determine univariate and multiple
variable hazard ratios (HR) and the multiple variable pre-
dictive value of AMPD1(2) carriage, conditioned on 10
other major CAD risk factors: age, gender, smoking status,
diabetic status, history of hypertension, history of hyperlip-
idemia, family history, renal failure, presentation and initial
therapy (SPSS v 9.0, Chicago, Illinois). The critical value
for entering and excluding variables in the model was set at
p 5 0.10.
RESULTS
Baseline patient characteristics. A total of 367 patients
with documented CAD was entered, and 52 patients
(14.2%) died during the mean of 3.5 6 1.0 year follow-up,
37 (10.1%) of CV causes. Selected patient characteristics at
study entry are summarized in Table 1 by survival status.
Patients averaged 66 6 10 years of age, and 79% were men.
Survivors were younger at baseline, had higher ejection
fractions and tended to be men and smokers more fre-
quently than nonsurvivors.
Adenosine monophosphate deaminase-1 genotypic dis-
tributions are shown in Table 2 for all patients and for
survivors, those dying of any cause and those dying of a CV
cause. Of entered patients, 22.6% were heterozygous and
1.9% homozygous for the AMPD1(2) allele. Thus, 24.5%
were carriers of the polymorphic allele. In bivariate corre-
lation analyses, AMPD1(2) carriage was unassociated with
any other baseline factor, including ejection fraction.
AMPD1 genotype and survival. At the end of follow-up,
CV mortality was 4.4% (4/90) for AMPD1(2) allele carriers
compared with 11.9% (33/277) for noncarriers. Figure 1
shows the time-to-event (Kaplan-Meier) CV survival plot
as a function of AMPD1(2) allele carriage. A significant
difference in survival by AMPD1 genotype was observed
(log-rank statistic, 4.0, p 5 0.046). The HR of death for
AMPD1(2) carriage was 0.36 (0.13 to 1.0).
Adenosine monophosphate deaminase-1(2) carriage was
not associated with a reduction in noncardiovascular deaths
(5.5% in carriers, 3.6% in noncarriers). When all-cause
mortality was considered (CV plus non-CV), the difference
Abbreviations and Acronyms
AMISTAD 5 Acute Myocardial Infarction Study of
Adenosine
AMPD 5 adenosine monophosphate deaminase
CAD 5 coronary artery disease
CV 5 cardiovascular
HR 5 hazard ratio
MI 5 myocardial infarction
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was not significant (10.0% in AMPD1[2] carriers, 15.5% in
noncarriers; p 5 0.19).
In multiple variable Cox regression analysis, including 12
clinical and laboratory variables (age, gender, smoking,
diabetes, hypertension, hyperlipidemia, family history, total
cholesterol, renal failure, presenting diagnosis, therapy at
index hospitalization and AMPD1[2] carriage), only age
(HR, 1.11/year, p , 0.001) and AMPD1(2) carriage (HR,
0.36, confidence interval 0.13–1.02, Wald chi-square p 5
0.053) were selected as independent predictors of CV
mortality (Table 3).
The incomplete database for ejection fraction dissuaded
us from doing a formal determination of the relative
predictive value of the polymorphism in high and low
ejection fraction subgroups. However, the reduction in CV
mortality did appear to be prominent in those with low
(#40%) ejection fractions (0/9 with, vs. 13/34 without an
AMPD1[2] allele and documented low ejection fraction,
died).
In contrast with its value for secondary risk prediction,
AMPD1 polymorphism was not useful for prediction of the
presence or absence of CAD at initial angiography in an
expanded consecutive series that included subjects with
normal angiograms (not shown).
DISCUSSION
Study summary. We found that patients with angiographi-
cally documented CAD who were carriers of a common
genetic variant of the AMPD1 gene demonstrated improved
CV survival. The AMPD1 variant did not predict develop-
ment of CAD; rather, the effect appeared to be in prolong-
ing survival when heart disease was already present. Aden-
osine monophosphate deaminase-1 genotype was
unassociated with other risk factors, and its predictive value
was undiminished in multiple variable analyses (HR 5
0.36). We speculate that the dysfunctional AMPD1(2)
allele may lead to increased net production of adenosine
locally (in cardiac muscle [7]) and/or systemically (skeletal
muscle source [6]), affording increased levels of cardiopro-
tection during ischemic events. If these results are verified,
AMPD1 genotyping may provide useful prognostic, mech-
anistic and therapeutic insights into CAD progression and
prognosis.
Previous work. Recently, Loh et al. (6) reported an im-
proved clinical outcome associated with AMPD1(2) allele
carriage in a group of 132 patients with advanced heart
failure referred for cardiac transplant evaluation. The mu-
tant AMPD1 allele was associated with an extended time
Table 1. Patient Characteristics at Baseline by Survival Status
Characteristic All Patients Survivors Deaths CV Deaths P1 P2
Number 367 315 52 37 — —
Age (yr) (X 6 SD) 66.1 6 10.1 65.1 6 9.9 72.0 6 8.9 73.6 6 7.0 0.000 0.000
Gender (% male) 79.0 79.7 75.0 67.6 0.44 0.07
Diabetes (%) 19.6 19.0 23.1 24.3 0.50 0.45
Smoker (%) 25.9 27.6 15.4 10.8 0.06 0.03
Fam Hx (%) 36.8 37.5 32.7 32.4 0.51 0.56
h/o HTN (%) 49.9 49.5 51.9 45.9 0.75 0.62
h/o HLip (%) 48.8 50.8 36.5 40.5 0.06 0.29
Chol (mg/dl) 183 6 47 184 6 47 177 6 49 178 6 47 0.34 0.49
(n Chol) (359) (308) (51) (37)
EF (%) 59.5 6 17.3 61.0 6 16.4 50.1 6 19.9 50.4 6 19.5 0.000 0.006
(n EF) (273) (237) (36) (25)
Allele carrier (%) 24.5 26.1 17.3 10.8
Death, last f/u (mo) 38.6 6 11.3 42.3 6 5.4 16.4 6 12.3 14.8 6 11.4 — —
P1 compares patients dying from any cause with survivors. P2 compares patients dying from cardiovascular causes with others.
Allele 5 AMPD1(2) variant allele; Chol 5 cholesterol; CV 5 cardiovascular; EF 5 ejection fraction; Fam Hx 5 family history; f/u 5 follow-up; HLip 5 hyperlipidemia;
HTN 5 hypertension.
Table 2. Genotypic Distributions and Allelic Frequencies of AMPD1 Gene Polymorphism Among Patients by Survival Status
Group
Wild type
(1/1)
n (%)
Heterozygote
(1/2)
n (%)
Homozygote
(2/2)
n (%)
WT
(1)
Allele
Variant
(2)
Allele
A. All patients/all deaths
Survivors 234 (74.3) 76 (24.1) 5 (1.6) 544 (86.3) 86 (13.7)
Deaths 43 (82.7) 7 (13.5) 2 (3.8) 93 (89.4) 11 (10.6)
Total 277 (75.5) 83 (22.6) 7 (1.9) 637 (86.8) 97 (13.2)
B. CV deaths/CV survivors
No CV death 244 (73.9) 79 (23.9) 7 (2.1) 567 (85.9) 93 (14.1)
CV Deaths 33 (89.2) 4 (10.8) 0 (0) 70 (94.6) 4 (5.4)
Total 277 (75.5) 83 (22.6) 7 (1.9) 637 (86.8) 97 (13.2)
For A, death by genotype contingency table gives p 5 0.15 (chi-square). For B, CV death by genotype gives p 5 0.11 (chi-square), p 5 0.063 (likelihood ratio) or p 5 0.038
(linear-by-linear association).
CV 5 cardiovascular; WT 5 wild type.
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from the first hospitalization for heart failure to evaluation
for transplantation, with an HR for transplant-free survival
of 4.6. Our study is the first to confirm and extend these
findings to patients with CAD who were not selected by
ejection fraction or heart failure and who were studied
prospectively after angiographic diagnosis.
Mechanisms of benefit. Loh et al. (6) speculated that the
mechanism of benefit could be related to enhanced produc-
tion of adenosine in skeletal muscle that could increase
circulating levels of adenosine, leading to cardioprotection.
Feldman et al. (7) editorialized that the short circulating
half-life of adenosine argued for a primarily local (myocar-
dial) increase in net adenosine and hypothesized that
adenosine levels might be increased in cardiac muscle in
patients carrying the variant allele (7). Adenosine, released
by myocytes during ischemic stress (13), has been studied
extensively for a cardioprotective role although this remains
to be completely defined (14,15). As reviewed by Mahaffey
et al. (15), adenosine has been reported to replenish high-
energy phosphates, inhibit oxygen free radical formation
and neutrophil activation and accumulation, improve mi-
crovascular function and participate in myocardial ischemic
preconditioning in experimental models of occlusion/
reperfusion, improving cardiac perfusion and function.
Earlier human studies (16,17), promising in themselves,
have been followed by a larger (n 5 236 patients) controlled
study, the Acute Myocardial Infarction Study of Adenosine
(AMISTAD) (15). In AMISTAD, adenosine (70 mg/kg/
min) infused for 3 h as an adjunct to thrombolytic therapy
reduced radionuclide infarct size by 33% (p 5 0.03). A
larger trial to assess clinical events was proposed.
The role of AMPD1 in cardiac muscle is less well studied
than in skeletal muscle although it has been reported to be
expressed (together with AMPD2) in mammalian heart
(18). To date, neither myocardial nor skeletal muscle
adenosine levels have been measured in disease states and by
AMPD1 genotype.
Whatever the precise mechanism of adenosine’s benefit,
the AMPD1(2) allele may provide carriers with an endog-
enous source of increased myocardial adenosine, improving
outcomes in those with CAD at high risk for future
ischemic events.
Study strengths and limitations. This study extends pre-
vious work on clinical consequences of the AMPD1 poly-
morphism (6) by including a larger and broader spectrum of
patients and evaluating their clinical course entirely prospec-
tively. Adenosine monophosphate deaminase-1 genotype
was unassociated with other risk factors, and its association
with CV survival was independent of other tested risk
factors in multiple variable analysis. However, the study is
only moderate in size, and the number of clinical events is
relatively small, so that the confidence intervals for CV
survival extension associated with AMPD1(2) are broad.
Similarly, the database for determining the relative protec-
tive effect of the variant as a function of ejection fraction is
limited. Also, the study did not directly assess potential
mechanisms of apparent benefit. The similarity of genotypic
frequencies in our CAD group to that in the general
population further supports our observation about the ab-
sence of an effect on the development of CAD. Thus, for
future studies disease progression or prognosis may be a
better focus than disease development. In conclusion, our
findings, although promising, should be verified and ex-
Figure 1. Kaplan-Meier survival-time plot for cardiovascular death by
AMPD1 genotype (wild type vs. variant heterozygote or homozygote).
There are four events (4.4%) among 90 patients carrying the mutant
polymorphism and 33 events (11.9%) among noncarriers, a statistically
significant difference (log-rank statistic 4.0, p 5 0.046; Breslow statistic
4.1, p 5 0.043). Solid line 5 AMPD1(2) variant carrier; dotted line 5
variant noncarrier.
Table 3. Cox Multiple Variable Logistic Regression Model* for Cardiovascular Death
Factor Wald HR(Exp B) Lower CI Upper CI p Value
AMPD(2) 3.74 0.36 0.13 1.02 0.053
Age/yr 21.96 1.11 1.06 1.16 ,0.001
*Using Backward Stepwise Conditional Logistic Regression method (SPSS v 9.0), entering age (year); male gender, h/o
hypertension, h/o hyperlipidemia, diabetes, family history, smoking, renal failure, adenosine monophosphate deaminase (2)
allele carriage (2/1 or 2/2), all yes/no; presentation (stable angina, unstable angina, myocardial infarction), therapy at index
hospitalization (medical, angioplasty, or surgery) and total cholesterol (mg/dl). Systolic blood pressure (mm Hg) and diastolic
blood pressure (mm Hg) were included in separate analyses (with less complete datasets) with similar results. There were 358
patients with complete datasets entered and 37 events. P to exclude variables stepwise was 0.10 (ejection fraction was not entered
because of the large resulting number of incomplete datasets; that is, n 5 265).
CI 5 95% confidence interval; Exp B 5 exponential B; HR 5 hazard ratio.
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tended in larger and longer-term studies. If validated, they
suggest that AMPD1 genotyping may provide useful prog-
nostic, mechanistic and therapeutic insights into survival in
patients with CAD as well as those with congestive heart
failure.
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